<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03982680</url>
  </required_header>
  <id_info>
    <org_study_id>cholangiocarcinoma</org_study_id>
    <nct_id>NCT03982680</nct_id>
  </id_info>
  <brief_title>Toripalimab Combined With Gemcitabine/5--fluoropyrimidine for Advanced Cholangiocarcinoma</brief_title>
  <official_title>Clinical Study of Toripalimab Monoclonal Antibody Combined With Gemcitabine/5--fluoropyrimidine in the Treatment of Advanced Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangmen Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangmen Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a phase II clinical trial of single arm. The purpose is to evaluate the safety
      and efficacy of anti-PD-1 antibody Toripalimab combined with
      chemotherapy(gemcitabine+5-fluorine pyrimidine) in unresectable advanced cholangiocarcinoma
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All patients were given Toripalimab 3 mg/kg (day 1 and 15); Gem+5-FU (Gem 1250mg/m2+CF 200 mg/m2+5-FU400 mg/m2 intravenous drip+5-FU 2.4-3.6 g/m2 continuous intravenous drip for 48 hours), the first and fifteenth days, four weeks for a cycle, a total of four cycles. After 4 cycles, Toripalimab was maintained at 3 mg/kg Q3 w for a total of 1 year if the disease was not progressing or toxic side effects were tolerated.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6-month PFS rate</measure>
    <time_frame>6-month after the beginning of first line systemic therapy</time_frame>
    <description>the rate of 6-month progression free survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mPFS</measure>
    <time_frame>from the beginning of the first line systemic therapy until the date of first documented progression or date of death from any cause,whichever came first,assessed up to 24 months</time_frame>
    <description>the median of progression free survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxic side effects</measure>
    <time_frame>from the beginning of the first line systemic therapy until the end of follow-up,assessed up to 24 months</time_frame>
    <description>assess according to the National Cancer Institute-Common Terminology Criteria for Adverse Events 3.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>from the beginning of the first line systemic therapy until the date of completion of therapy,assessed up to 13 months</time_frame>
    <description>the objective response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>from the beginning of the first line systemic therapy until the date of completion of therapy,assessed up to 13 months</time_frame>
    <description>the disease control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year OS rate</measure>
    <time_frame>1 year after the beginning of the first line systemic therapy</time_frame>
    <description>the rate of 1-year overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mOS</measure>
    <time_frame>from the beginning of the first line systemic therapy until the date of death from any cause,assessed up to 24 months</time_frame>
    <description>the median of overall survival</description>
  </secondary_outcome>
  <other_outcome>
    <measure>the value of PD-1/PD-L1</measure>
    <time_frame>from the beginning of the first line systemic therapy until the end of follow-up,assessed up to 24 months</time_frame>
    <description>to analyze the predictive value of PD-1/PD-L1 for efficacy and toxicity</description>
  </other_outcome>
  <other_outcome>
    <measure>the value of MMR</measure>
    <time_frame>from the beginning of the first line systemic therapy until the end of follow-up,assessed up to 24 months</time_frame>
    <description>to analyze the predictive value of MMR for efficacy and toxicity</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>Toripalimab combined with Gem/5-FU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients were given Toripalimab 3 mg/kg (day 1 and 15); Gem+5-FU (Gem 1250mg/m2+CF 200 mg/m2+5-FU400 mg/m2 intravenous drip+5-FU 2.4-3.6 g/m2 continuous intravenous drip for 48 hours), the first and fifteenth days, four weeks for a cycle, a total of four cycles.After 4 cycles, Toripalimab was maintained at 3 mg/kg Q3 w for a total of 1 year if the disease was not progressing or toxic side effects were tolerated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab</intervention_name>
    <description>3mg/kg on d1 and d15 q4W*4cycles，then 3mg/kg q3w for 1 year in total</description>
    <arm_group_label>Toripalimab combined with Gem/5-FU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1250mg/m2 on d1 and d15 q4W*4cycles</description>
    <arm_group_label>Toripalimab combined with Gem/5-FU</arm_group_label>
    <other_name>Gem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5- fluorine pyrimidine</intervention_name>
    <description>400mg/m2 intravenous injection plus 5-FU 2.4g-3.6g/m2 continuous intravenous drip for 48h on d1 and d15 q4W*4cycles</description>
    <arm_group_label>Toripalimab combined with Gem/5-FU</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically or cytologically confirmed cholangiocarcinoma

          -  stage IV disease,no system therapy for advanced disease

          -  one or more lesions that can be measured by imaging assessment

          -  18 to 70 years of age and life expectancy exceeds 3 months

          -  adequate specimens for detection of PD-1/PD-L1 and MMR

          -  karnofsky performance status(KPS) score ≥70%

          -  routine blood routine, liver and kidney function and electrocardiogram were basically
             normal without contraindication of chemotherapy.

        Exclusion Criteria:

          -  dual cancers other than cholangiocarcinoma

          -  metastasis of central nervous system

          -  unreleased biliary obstruction

          -  acute infections requiring treatment

          -  non-infectious pneumonia requires glucocorticoid therapy, active autoimmune diseases,
             or systemic immunosuppressive therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu gengsheng, master</last_name>
    <role>Study Director</role>
    <affiliation>jiangmen cenctral hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deng wenjing, master</last_name>
    <phone>(+86)07503165905</phone>
    <email>wjdeng2011@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yu gengsheng, master</last_name>
    <phone>(+86)07503165915</phone>
    <email>gengsheng_yu@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jiangmen central hospital</name>
      <address>
        <city>Jiangmen</city>
        <state>Guangdong</state>
        <zip>529000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenjing Deng, master</last_name>
      <phone>+8607503165905</phone>
      <email>wjdeng2011@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Gengsheng Yu, master</last_name>
      <phone>+8607503165905</phone>
      <email>gengsheng_yu@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Jan 10;385(9963):117-71. doi: 10.1016/S0140-6736(14)61682-2. Epub 2014 Dec 18.</citation>
    <PMID>25530442</PMID>
  </reference>
  <reference>
    <citation>Jain A, Javle M. Molecular profiling of biliary tract cancer: a target rich disease. J Gastrointest Oncol. 2016 Oct;7(5):797-803. Review.</citation>
    <PMID>27747093</PMID>
  </reference>
  <reference>
    <citation>Takakura H, Domae S, Ono T, Sasaki A. The Immunological Impact of Chemotherapy on the Tumor Microenvironment of Oral Squamous Cell Carcinoma. Acta Med Okayama. 2017 Jun;71(3):219-226. doi: 10.18926/AMO/55204.</citation>
    <PMID>28655941</PMID>
  </reference>
  <reference>
    <citation>Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B, Mueller B, Quaratino S, Sabatos-Peyton C, Petruzzelli L, Engelman JA, Dranoff G. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer. 2017 May;17(5):286-301. doi: 10.1038/nrc.2017.17. Epub 2017 Mar 24. Review.</citation>
    <PMID>28338065</PMID>
  </reference>
  <reference>
    <citation>Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, Koshiji M, Nambu Y, Furuse J, Miyazaki M, Nimura Y. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010 Aug 10;103(4):469-74. doi: 10.1038/sj.bjc.6605779. Epub 2010 Jul 13.</citation>
    <PMID>20628385</PMID>
  </reference>
  <reference>
    <citation>Morizane C, Ueno M, Ikeda M, Okusaka T, Ishii H, Furuse J. New developments in systemic therapy for advanced biliary tract cancer. Jpn J Clin Oncol. 2018 Aug 1;48(8):703-711. doi: 10.1093/jjco/hyy082. Review.</citation>
    <PMID>29893894</PMID>
  </reference>
  <reference>
    <citation>Sabbatino F, Villani V, Yearley JH, Deshpande V, Cai L, Konstantinidis IT, Moon C, Nota S, Wang Y, Al-Sukaini A, Zhu AX, Goyal L, Ting DT, Bardeesy N, Hong TS, Fernandez-del Castillo C, Tanabe KK, Lillemoe KD, Ferrone S, Ferrone CR. PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. Clin Cancer Res. 2016 Jan 15;22(2):470-8. doi: 10.1158/1078-0432.CCR-15-0715. Epub 2015 Sep 15.</citation>
    <PMID>26373575</PMID>
  </reference>
  <reference>
    <citation>Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014 Oct 1;20(19):5064-74. doi: 10.1158/1078-0432.CCR-13-3271. Epub 2014 Apr 8.</citation>
    <PMID>24714771</PMID>
  </reference>
  <reference>
    <citation>Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011.</citation>
    <PMID>25428504</PMID>
  </reference>
  <reference>
    <citation>Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.</citation>
    <PMID>22658127</PMID>
  </reference>
  <reference>
    <citation>Gou M, Zhang Y, Si H, Dai G. Efficacy and safety of nivolumab for metastatic biliary tract cancer. Onco Targets Ther. 2019 Jan 25;12:861-867. doi: 10.2147/OTT.S195537. eCollection 2019.</citation>
    <PMID>30774373</PMID>
  </reference>
  <reference>
    <citation>Asaoka Y, Ijichi H, Koike K. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 Nov 12;373(20):1979. doi: 10.1056/NEJMc1510353.</citation>
    <PMID>26559583</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 7, 2019</study_first_submitted>
  <study_first_submitted_qc>June 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2019</study_first_posted>
  <last_update_submitted>July 13, 2019</last_update_submitted>
  <last_update_submitted_qc>July 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jiangmen Central Hospital</investigator_affiliation>
    <investigator_full_name>yu gengsheng</investigator_full_name>
    <investigator_title>Vice director of Oncology department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

